Vericel Corporation (VCEL) 株式分析

企業概要

Vericel Corporation is a commercial-stage biopharmaceutical enterprise engaged in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products tailored for the sports medicine and severe burn care markets within North America. The company operates within the healthcare sector, specifically the biotechnology industry, where it focuses on leveraging autologous cell technology to address specific clinical needs in tissue repair and wound management. Vericel currently holds a market capitalization of 17 億 3000 万ドル (1.73B), generates annual revenue (TTM) of 2 億 7626 万ドル (276.26M), and employs a workforce of 398 people. These valuation and revenue figures indicate that the company has established a significant operational footprint in a niche biotechnology segment, positioning it as a mid-to-large-cap player capable of sustaining substantial research and development expenditures while maintaining a diverse employee base for its specialized manufacturing processes.

財務健全性

Vericel Corporation reported a trailing twelve-month revenue of 2 億 7626 万ドル (276.26M) with a net income of 1 億 652 万ドル (16.52M) and an EBITDA of 2 億 259 万ドル (22.59M). The substantial gap between the gross revenue and the net income reveals a cost structure where operating expenses, including cost of goods sold and administrative costs, consume approximately 94% of the total revenue before interest and taxes. The company generated free cash flow of 1 億 605 万ドル (16.05M), which signifies positive financial flexibility allowing for capital allocation toward expansion or debt reduction without relying on external financing. Profitability metrics show a gross margin of 74.4%, an operating margin of 24.1%, and a profit margin of 6.0%, indicating that while the company retains a high portion of revenue after direct production costs, significant overhead expenses reduce the final bottom-line profitability. On the balance sheet, the company holds cash reserves of 13 億 750 万ドル (137.50M) against total debt of 9 億 689 万ドル (96.89M), resulting in a debt-to-equity ratio of 27.32, which suggests a conservative leverage position given that cash significantly exceeds debt obligations. Liquidity is robust as evidenced by a current ratio of 5.03, indicating that the company possesses more than five times the current assets necessary to cover its short-term liabilities. Efficiency ratios further clarify management effectiveness with a return on equity of 5.1% and a return on assets of 1.5%, reflecting the capital-intensive nature of biotechnology operations where asset turnover impacts overall return generation.

バリュエーション評価

Valuation metrics indicate a premium pricing for future growth expectations, with a trailing P/E ratio (TTM) of 103.12 compared to a forward P/E of 42.27, implying that the market anticipates a substantial expansion in earnings per share over the coming year. The price-to-book ratio stands at 4.86, suggesting that the market values the company's equity at nearly five times its book value, reflecting the high intangible asset content and future potential inherent in biotechnology firms. Alternative valuation measures include a price-to-sales ratio of 6.27 and an EV/EBITDA of 74.68, which suggest that investors are willing to pay a significant multiple relative to both sales and cash earnings due to the high growth trajectory expected in the cellular therapy sector. Price volatility analysis shows a 52-week high of 45.97 and a 52-week low of 28.95, providing a range within which the stock has traded, though the current market price relative to this specific range requires calculation based on real-time data not provided in the static facts. The stock exhibits a beta of 1.21, indicating that the price volatility of Vericel Corporation is approximately 21% higher than the broader market, making it a relatively aggressive investment compared to the S&P 500.

Growth & Income

Revenue growth year-over-year is recorded at 23.3% while earnings growth year-over-year is 18.9%, demonstrating that earnings are expanding at a slightly slower rate than top-line revenue, which may indicate increasing operating leverage or cost pressures as the company scales. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all net income of 1 億 652 万ドル (16.52M) is retained within the business to fund research, development, and capital expenditures rather than being distributed to shareholders. This reinvestment strategy is typical for commercial-stage biopharmaceutical companies seeking to accelerate product pipelines and market penetration in sports medicine and burn care. The overall growth and income profile presents a high-growth, non-income-generating asset where shareholder returns are derived primarily from capital appreciation driven by the expansion of revenue and earnings rather than current cash distributions.